|Supplied by:||European Collection of Authenticated Cell Cultures (ECACC)|
|Culture Type:||Cell line|
|Collection:||ECACC General Collection|
|Cell Line Name:||EZZ (TOU II-4)|
|Citation Guidance:||If use of this culture results in a scientific publication, it should be cited in the publication as: EZZ (TOU II-4) (ECACC 93093003)|
|Keywords:||Human B cell lymphocyte, EBV transformed|
|Cell Line Description:||Peripheral blood lymphocytes from a healthy male Tunisian, immortalised by EBV transformation. The cell line contains the following deletion, at the homozygous state, in the human immunoglobulin heavy locus (IGH on chromosome 14 at 14q32.33), of 6 IGHC genes: on both chromosomes 14, deletion I (del G1-EP1-A1-GP-G2-G4). The Gm-Am genotype is Gm5*; - ; - A2m2/Gm5*; - ; - A2m2 (Gm b*; - ; - A2m2/Gm b*; - ; - A2m2). Gm allotypes are indicated in the order G3m; G1m; G2m. The absence of G1m and G2m allotypes due to the deletion of the IGHG1 and IGHG2 genes is indicated by (-). The EZZ deletion (deletion I), which encompasses 160 kb involves two highly homologous regions located 13 kb downstream of IGHG3 and 13 kb downstream of IGHG4. AAn Epstein-Barr-transformed lymphoblastoid cell line is available, from the mother heterozygous for deletions I and II, as TOU (TOU I-2) (93093001) and, from one brother heterozygous for deletions I and II, as MOH (TOU II-3) (93093002).An Epstein-Barr-transformed lymphoblastoid cell line with an identical deletion I, at the homozygous state, is available, from one member of another Tunisian family, as TAK3 (93093004).|
|Tissue of Origin:||blood|
|GMO Status:||Genetically Modified Organism Class 1 (GMO1)|
Unless specified otherwise, at the European Collection of Authenticated Cell Cultures (ECACC) we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines. ACDP = Advisory Committee on Dangerous Pathogens (UK)
All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Hyperlinks to MSDS documents:
Frozen cell cultures Material Safety Data Sheet
Growing cell cultures Material Safety Data Sheet
Nucleic acids derived from cell cultures Material Safety Data Sheet
|Subculture Routine:||Maintain cultures at 5-9x100,000 cells/ml; 5% CO2; 37Â°C.|
|Culture Medium:||RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).|
|Depositor:||Prof M-P Lefranc and Prof G Lefranc, Laboratoire d'ImmunoGenetique Moleculaire (LIGM), Universite de Montpellier|
|References:||Lefranc M-P, Lefranc G, Rabbitts TH. 1982 Inherited deletion of immunoglobulin heavy chain constant region genes in normal human individuals. Nature 300(5894):760-2. PMID: 6817143|
|Additional Bibliography:||Keyeux G, Lefranc G, Lefranc M-P. 1989 A multigene deletion in the human IGH constant region locus involves highly homologous hot spots of recombination. Genomics 5(3):431-41. PMID: 2613231|
|Patents:||None specified by Depositor|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
Please confirm your country of origin from the list below.